Migraine Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Migraine Overview

A neurologic condition called migraine frequently results in a severe headache. The headache occurs in bursts, and occasionally it’s accompanied by nausea, vomiting, and light sensitivity. The most common cause of impairment in the world is migraine. About 15% of Americans suffer from migraines. Most migraine sufferers believe that individuals who do not suffer from them frequently underestimate their illness.

“Migraine Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Migraine Market.

The Migraine Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Migraine Pipeline Report:

• Companies across the globe are diligently working toward developing novel Migraine treatment therapies with a considerable amount of success over the years. Migraine Key players such as – Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc., AEON Biopharma, Inc., Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, Pfizer, and others, are developing therapies for the Migraine treatment 

• Migraine Emerging therapies such as – PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, Zavegepant, and others are expected to have a significant impact on the Migraine market in the coming years.  
• In May 2022, Axsome Therapeutics, Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine 
• In August 2022, Axsome Therapeutics, Inc. initiated a trial titled, “An Open-Label, Multiple-Dose Evaluation ofthe Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults With a PriorInadequate Response to an Oral CGRP Inhibitor

Route of Administration

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Migraine Pipeline Therapeutics Assessment

• Migraine Assessment by Product Type
• Migraine By Stage and Product Type
• Migraine Assessment by Route of Administration
• Migraine By Stage and Route of Administration
• Migraine Assessment by Molecule Type
• Migraine by Stage and Molecule Type

DelveInsight’s Migraine Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Migraine Therapeutics Market include:

Key companies developing therapies for  Migraine are – GlaxoSmithKline, Merck, and Pfizer are the three biggest players in the migraine market with products such as Imitrex, Amerge, Maxalt, Relpax, Teva, Amgen, Eli Lilly and Lundbeck, and others

Emerging Migraine Drugs Under Different Phases of Clinical Development Include:

• PUR-3100: Pulmatrix
• UB-313: Vaxxinity, Inc.
• TNX-1900: Tonix Pharmaceuticals, Inc.
• ABP-450: AEON Biopharma, Inc.
• LY3451838: Eli Lilly and Company
• STS-101: Satsuma Pharmaceuticals
• AXS 07: Axsome Therapeutics
• Zavegepant: Pfizer

Get a Free Sample PDF Report to know more about Migraine Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/migraine-pipeline-insight

Migraine Pipeline Analysis:

The Migraine pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
• Migraine key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Migraine product details are provided in the report. Download the Migraine pipeline report to learn more about the emerging Migraine therapies

Migraine Pipeline Market Drivers

• Increasing prevalence of Migraine
• Significant progress is being made in the preventative treatment of chronic migraine
• Growing awareness regarding migraine

Migraine Pipeline Market Barriers

• Lack of proper diagnosis
• Various side-effects associated with the available drugs

Scope of Migraine Pipeline Drug Insight    

• Coverage: Global
• Key Migraine Companies: Pulmatrix, Vaxxinity, Inc., Tonix Pharmaceuticals, Inc., AEON Biopharma, Inc., Eli Lilly and Company, Satsuma Pharmaceuticals, Axsome Therapeutics, Pfizer, and others
• Key Migraine Therapies: PUR-3100, UB-313, TNX-1900, ABP-450, LY3451838, STS-101, AXS 07, Zavegepant, and others
• Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
• Migraine Market Dynamics: Migraine market drivers and Migraine market barriers 

Request for Sample PDF Report for Migraine Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Migraine drugs and therapies 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting